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Abstract: Introduction: The PI3K-AKT-mTOR pathway may be involved in the 
development of CNS metastasis from breast cancer. Accordingly, here we 
explored whether single nucleotide polymorphisms (SNP) of this pathway 
are associated with altered risk of CNS metastasis formation in 
metastatic breast cancer patients.  
Methods: The GENEOM study (NCT00959556) included blood sample collection 
from breast cancer patients treated in the neoadjuvant, adjuvant or 
metastatic setting. We identified patients with CNS metastases for 
comparison with patients without CNS metastasis, defined as absence of 
neurological symptoms or normal brain MRI before death or during 5-year 
follow-up. Eighty-eight SNP of PI3K-AKT-mTOR pathway genes were selected 
for analysis: AKT1 (17 SNP), AKT2 (4), FGFR1 (2), mTOR (7), PDK1 (4), 
PI3KR1 (11), PI3KCA (20), PTEN (17), RPS6KB1 (6). 
Results: Of 342 patients with metastases, 207 fulfilled the inclusion 
criteria: 107 patients remained free of CNS metastases at last follow-up 
or date of death whereas 100 patients developed CNS metastases. Among 
clinical parameters, hormonal and HER2 status as well as tumor vascular 
emboli were associated with risk of CNS metastasis. Only PI3KR1-rs706716 
was associated with CNS metastasis in univariate analysis after 
Bonferroni correction (p<0.00085). Multivariate analysis showed 
associations between AKT1-rs3803304, AKT2-rs3730050, PDK1-rs11686903 and 
PI3KR1-rs706716 and CNS metastasis.  
Conclusion: PI3KR1-rs706716 may be associated with CNS metastasis in 
metastatic breast cancer patients and could be included in a predictive 
composite score to detect early CNS metastasis irrespective of breast 
cancer subtype. 
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Abstract  
Introduction: The PI3K-AKT-mTOR pathway may be involved in the development of 
CNS metastasis from breast cancer. Accordingly, here we explored whether single 
nucleotide polymorphisms (SNP) of this pathway are associated with altered risk of 
CNS metastasis formation in metastatic breast cancer patients.  
Methods: The GENEOM study (NCT00959556) included blood sample collection 
from breast cancer patients treated in the neoadjuvant, adjuvant or metastatic 
setting. We identified patients with CNS metastases for comparison with patients 
without CNS metastasis, defined as absence of neurological symptoms or normal 
brain MRI before death or during 5-year follow-up. Eighty-eight SNP of PI3K-AKT-
mTOR pathway genes were selected for analysis: AKT1 (17 SNP), AKT2 (4), FGFR1 
(2), mTOR (7), PDK1 (4), PI3KR1 (11), PI3KCA (20), PTEN (17), RPS6KB1 (6). 
Results: Of 342 patients with metastases, 207 fulfilled the inclusion criteria: 107 
patients remained free of CNS metastases at last follow-up or date of death whereas 
100 patients developed CNS metastases. Among clinical parameters, hormonal and 
HER2 status as well as tumor vascular emboli were associated with risk of CNS 
metastasis. Only PI3KR1-rs706716 was associated with CNS metastasis in 
univariate analysis after Bonferroni correction (p<0.00085). Multivariate analysis 
showed associations between AKT1-rs3803304, AKT2-rs3730050, PDK1-
rs11686903 and PI3KR1-rs706716 and CNS metastasis.  
Conclusion: PI3KR1-rs706716 may be associated with CNS metastasis in metastatic 
breast cancer patients and could be included in a predictive composite score to 
detect early CNS metastasis irrespective of breast cancer subtype. 
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Text  
INTRODUCTION 
Breast cancer represents the most common cancer in women. Central nervous 
system (CNS) metastases occur in up to 10% of patients [1] and herald poor 
outcome: survival varies from 2.7 to 26.8 months with solid brain metastases, by 
breast cancer subtype [2] and is 4 months with leptomeningeal metastases [3-6]. 
Treatment of CNS metastasis aims not only for prolonging survival, but also at 
prevention or delay of neurological deterioration [7].  
The identification of patients at risk could help to increase the efficacy of treatment of 
CNS metastasis. While cerebrospinal imaging is not part of standard follow-up in 
patients without neurological signs, the identification of subgroups of patients at risk 
could allow the implementation of more intensive follow-up and early intervention 
strategies. 
Brain metastases risk is increased in triple-negative and human epidermal growth 
factor receptor (HER) 2-positive tumors [1, 8-14]. Risk factors for leptomeningeal 
metastases include opening of the ventricular system during surgery for solid brain 
metastases and resection of cerebellar metastases [15,16] and breast cancer 
patients specifically lobular subtype and triple-negative tumors [4,5,6,17]. 
Genetic variations could also help to define populations at risk. Single nucleotide 
polymorphisms (SNP) represent the most frequent type of variations of the human 
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genome [18]: they represent a single nucleotide variation at a specific position in the 
genome present at a frequency of 1%-50% in the general population that is 
maintained through heredity. While not causing disease, SNP can modify protein 
structure and function and thereby influence susceptibility to disease, including 
cancer [18]. 
The PI3K-AKT-mTOR pathway controls cell cycle, survival, differentiation, 
proliferation, motility, metabolism, and genomic stability and may be the most 
frequently activated pathway in human cancer [19,20,21]. Moreover, it also regulates 
the behavior of normal cells and contributes to host cell tumor cell interactions, e.g., 
during angiogenesis and inflammation [21-27]. PI3K-AKT-mTOR pathway genetic 
lesions are frequent in breast cancer and may mediate resistance to HER2-targeted 
agents and hormonal agents [28]. Activation of the PI3K pathway has specifically 
been observed in brain metastases from breast cancer, regardless of subtype as 
defined by hormone receptor or HER2 status [29,30], potentially mediated by the loss 
of PTEN expression as demonstrated in paired primary tumor and brain metastasis 
samples [31]. In fact, the loss of PTEN may directly promote brain invasiveness of 
metastatic breast cancer cells [27]. Here we sought to identify SNP of the PI3K-AKT-
mTOR pathway associated with increased risk of CNS metastasis formation in 
patients with metastatic breast cancer. 
 
 
MATERIALS AND METHODS 
Patients 
We conducted a secondary analysis in a subpopulation of patients from the 
GENEOM study (NCT00959556) that aimed at identifying constitutional genetic 
 5 
variants predictive of response to chemotherapy and hormone therapy in adult 
patients with histologically confirmed breast cancer and included 914 women 
between November 2007 and January 2012. Our aim was to identify biomarkers of 
CNS metastasis risk among patients who developed metastases, at diagnosis of 
breast cancer or during follow-up (n=342) (Supplementary Note 1). Among patients 
fulfilling the inclusion criteria (n=207), CNS metastases were diagnosed at initial 
diagnosis of breast cancer or during follow-up, on brain MRI (n=87, 87%) or cranial 
CT (n=13, 13%). Histological confirmation was obtained in 10 brain metastasis 
patients. Leptomeningeal metastasis was defined by the presence of tumor cells in 
the cerebrospinal fluid (CSF) (n=25) or by characteristic MRI findings in a patient 
presenting with clinical signs suggestive of leptomeningeal metastases in the 
absence of positive CSF cytology (n=15). In 9 patients, the diagnosis was based on 
clinical evaluation and brain imaging only. Patients with extra-CNS metastasis only 
were defined by the absence of neurological symptoms or signs or normal brain MRI 
before death or during at least 5 years of follow-up after the diagnosis of the first 
metastasis. Patients with neurological symptoms of unclear origin, unclear cause of 
death, or follow-up below 5 years after the diagnosis of the first metastasis were 
excluded. 
 
SNP selection 
SNP of the PI3K-AKT-mTOR pathway were selected based on a systematic literature 
search. Eligible SNP had to have a minor allele frequency  0.05 in a European 
population, based on a 1000 genomes database 
(https://phase3browser.1000genomes.org/index.html). Eighty-eight SNP of the PI3K-
AKT-mTOR pathway were finally considered for the genomic analysis. Two were 
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excluded (AKT1 rs3803304 and AKT1-rs2498786) due to a discordance between 
frequencies observed in our population and the database. A total of 86 SNP was 
finally analyzed (Supplementary Table 1). Details on genomic analyses and SNP 
studies are provided in Supplementary Note 2. 
 
Statistical analysis 
Overall survival (OS) was defined as time interval from diagnosis until death from any 
cause using the Kaplan-Meier method. Patients alive were censored at last follow-up. 
Cumulative incidence of CNS metastases was estimated using a competing risk 
approach considering the time interval from diagnosis of first metastasis to the date 
of diagnosis of CNS metastases, with death without CNS metastases considered as 
a competing event; patients alive without CNS metastases were censored at the date 
of last follow-up. Associations between CNS metastases and clinical parameters and 
genomic parameters were evaluated using sub-distribution hazard ratios estimated in 
Fine and Gray regression models. The first step consisted in the analysis of clinical 
factors. A multivariate competing risk regression model was performed for 
parameters significantly associated with CNS metastasis in univariate analysis 
(p<0.05). 
A similar type of modeling was used for the second step of the analysis, evaluating 
the association of genomic parameters with the risk of CNS metastases. A SNP was 
considered as evaluable after verification of comparison for genotypic frequencies 
according to the Hardy-Weinberg equilibrium. SNP were excluded if the minor allele 
frequency was below 1%, or if genotyping analyses were performed in less than 90% 
of the patients of the cohort. Patients with less than 90% of SNP analyzed were 
excluded. For each SNP, the analysis was performed considering a dominant model 
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(dominant genotype versus others), recessive model (recessive genotype versus 
others) or log-additive model (3 ordered genotypic classes). The significance level 
was set to p<0.05, and a Bonferroni correction for multiple testing was also 
determined according to the number of independent SNP evaluated 
(threshold=0.05/number of independent SNP with r2<0.8). SNP significantly 
associated with CNS metastasis in univariate analysis (using level p<0.05) were 
included in a multivariate competitive risks regression model including a step by step 
selection procedure of variables. Akaike information criterion (AIC) was applied for 
the selection of the appropriate SNP coding when several modellings were 
associated with CNS metastasis. A composite score was also computed from the 
estimated regression coefficients of the multivariate model including all SNP 
significant at a 5%-significant level. Lastly, the association of this genomic score with 
the risk of CNS metastases was evaluated in multivariate analysis adjusted for 
clinical parameters significantly linked to CNS metastasis. Confidence intervals were 
re-estimated using a boostrap approach with 1000 samplings. Harrell C 
discrimination index was computed. Statistical analyses were performed using Stata 
software (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, 
TX: StataCorp LP) and SNPassoc package of R software v3.3.1. 
 
RESULTS 
Clinical patient characteristics 
Among the 914 patients enrolled in GENEOM, 342 patients had metastatic disease, 
119 at diagnosis of breast cancer and 223 during follow-up. Among these 342 
patients, 135 patients were excluded, leading to a study population of 207 patients 
(Figure 1). The median follow-up of this cohort is 9.1 years (range 4.8-10.5) after the 
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diagnosis of first metastasis. Overall, 107 patients remained free of CNS metastases 
at last follow-up or date of death whereas 100 patients developed CNS metastases. 
Median time interval between first diagnosis of metastasis and first diagnosis of brain 
metastasis was 1.4 years (0-8.4); it was 2.1 years between first diagnosis of 
metastasis and first diagnosis of leptomeningeal metastasis. CNS metastasis was 
the first metastatic site in 8 patients (8%). Treatment of brain metastases included 
surgery in 10, stereotactic radiotherapy in 14, whole brain radiotherapy in 51, and 
pharmacotherapy in 53 patients. Treatment of leptomeningeal disease included intra-
cerebrospinal fluid pharmacotherapy in 28, focal radiotherapy in 5 and whole brain 
radiotherapy in 1, and systemic pharmacotherapy in 29 patients. At last follow-up, 
189 patients had died. Median overall survival was 5.3 years (95% CI 4.5-6.1) since 
breast cancer diagnosis and 2.8 years (95% CI 2.3-3.3) since first diagnosis of 
metastasis. Median overall survival after diagnosis of CNS metastasis was 4.7 
months (95% CI: 3.6-6.4) for brain metastases patients and 4 months (95% CI: 2.3-
4.9) for leptomeningeal metastases patients (Figure 2A,B,C).  
Patient characteristics and association of clinical characteristics with risk of CNS 
metastases are summarized in Table 1. Median age at breast cancer diagnosis was 
50 years (range, 22 to 79); age was not associated with occurrence of CNS 
metastasis. A lower time interval between breast cancer diagnosis and diagnosis of 
first metastasis was associated with an increased risk of CNS metastases whereas 
histology and Scarff Bloom Richardson scores were not. Cumulative incidence of 
CNS metastases was higher in patients with hormone receptor-positive and HER2-
positive or triple-negative tumors, as well as in patients with peritumoral emboli on 
univariate and multivariate analysis (Figure 2D,E). Initial treatment was not 
associated to the occurrence of CNS metastases (Supplementary Table 2).  
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SNP analyses 
Of 86 SNP, 3 were excluded from analysis: RPS56KB1-rs1292033 for not respecting 
the Hardy Weinberg equilibrium, and PI3KCA-rs17849071 and PI3KCA-rs7641889 
because 10.1% of patients could not be genotyped for these 2 SNP. No SNP had a 
minority allele frequency below 1%. The genotype of all patients was analyzed for 
more than 90% of SNP, and thus all patients were included in this analysis. Thus 83 
SNP were finally evaluated (Supplementary Table 1). Univariate analysis showed a 
significant association at a 5%-alpha level between the 7 of 83 SNP and the 
occurrence of CNS metastasis: AKT1-rs3803304, AKT2-rs3730050, AKT2-
rs8100018, PDK1-rs11686903, PDK1-rs11904366, PI3KR1-rs251408 and PI3KR1-
rs706716 (Table 2). After Bonferroni correction (p-value<0.00085), only PI3KR1-
rs706716 remained significantly associated with CNS metastasis. For the multivariate 
analysis including SNP associated with occurrence of CNS metastasis in univariate 
analysis at the 5%-alpha level, we excluded AKT2-rs8100018 since it had an 
identical distribution as AKT2-rs370050 in our population. Multivariate analysis 
confirmed an association between AKT1-rs3803304 CC, AKT2-rs3730050 AA, 
PDK1-rs11686903 TT and PI3KR1-rs706716 TT and the occurrence of CNS 
metastases (Table 2, Figure 3) with similar strength of association. When these 4 
SNP were combined into a score, three prognostic groups could be identified: five-
year cumulative incidence of CNS metastasis rate were 34.8%, 68.9% and 85.7% for 
patients with a score of 0 (no risk genotype), 1 (1 risk genotype) and 2 (2 risk 
genotypes). The score was significantly associated with the occurrence of CNS 
metastasis, with and without adjustment for the significant clinical parameters, 
hormone receptor status and HER2 status and peritumoral emboli (Table 3). 
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Confidence intervals of sub-distribution hazard ratios were re-estimated using a 
bootstrap approach and were close to the results previously obtained. The C index of 
Harrell, evaluating the discriminant capacity of the score was 0.607 (95%CI: 0.557-
0.657). The interaction test between the score and clinical parameters was not 
significant for both hormone receptors status and HER2 status, and peritumoral 
emboli (Supplementary Table 3). 
 
 
DISCUSSION 
CNS metastases are a frequent and life-threatening complication of metastatic breast 
cancer that not only limits survival, but induces morbidity and greatly impairs quality 
of life. The established risk factors of CNS metastasis such as HER2-positive and 
triple-negative tumor status [1, 9-14, 32] were confirmed in the present cohort. 
Interestingly, we observed that peritumoral emboli were also associated with 
increased risk of CNS metastasis (Table 1, Figure 2E). We sought to explore 
variations of PI3K-AKT-mTOR pathway genes for association with increased risk of 
CNS metastasis in metastatic breast cancer. AKT1-rs3803304, AKT2-rs3730050, 
AKT2-rs8100018, PDK1-rs11686903, PDK1-rs11904366, PI3KR1-rs251408 and 
PI3KR1-rs706716 were associated with risk of CNS metastasis in univariate analysis 
at a 5% alpha level, however, after Bonferroni correction, only PI3KR1-rs706716 
remained significantly associated (Table 2). Multivariate analysis confirmed 
associations between AKT1-rs3803304, AKT2-rs3730050, PDK1-rs11686903 and 
PI3KR1-rs706716, and the risk of CNS metastasis. The risk was at least double for 
patients with AKT1-rs3803304 (CC), AKT2-rs3730050 (AA), PDK1-rs11686903 (TT) 
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and PI3KR1-rs706716 (TT). The combination of SNP into a score enhanced the 
predictive power (Table 3). 
None of these SNP has previously been reported in studies on CNS metastases or 
breast cancer. PI3KR1-rs706716 and PDK1-rs11686903 have not been associated 
with other diseases. AKT1-rs3803304 was associated with a lower risk of death in 45 
patients with recurrent or initially metastatic head and neck squamous cell carcinoma 
[33] and a better response to treatment was associated with this SNP in 45 
esophageal cancer patients with adenocarcinoma or squamous cell carcinoma who 
had undergone chemoradiotherapy and surgery [34]. AKT2-rs3730050 was 
associated with shorter survival in 319 patients with muscle-invasive and metastatic 
bladder cancer [35].  
An analysis of 16 SNP of 5 genes of the PI3K-AKT-mTOR pathway (PIK3CA, PTEN, 
AKT1, AKT2, FRAP1) and occurrence of brain metastases in 317 non-small cell lung 
cancer patients showed that AKT1-rs2498804, AKT1-rs2494732 and PIK3CA-
rs2699887 increased the risk of brain metastases at 24-months follow-up [36]. None 
of these SNP were identified as at risk of CNS metastases here. 
How precisely SNP in a given pathway modulate course of disease in cancer patients 
remains to be elucidated. PI3KCA mutations are the most common mutations of the 
PI3K pathway in breast cancer, depending on the subtype of cancer, with the lowest 
rate in triple negative cancer. The prognostic role of PI3KCA mutations remains 
controversial, but they tend to be associated with more favorable outcomes [28]. 
Other alterations of the PI3K-AKT-mTOR pathway in breast cancer include PI3KR1 
mutations (3%), decreased PI3KR1 expression (62%), AKT1 mutations (3%) and 
overexpression (25.3%), PTEN mutations (2-12.5%), and PTEN loss (28%) [20, 28, 
37]. An alteration of at least one parameter of PI3K pathway has been reported in 
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72% of tumors [37]. Among 52 breast cancer brain metastases and 12 matched 
primary breast cancers, expression of p-AKT and p-S6, and lack of PTEN expression 
were found in 75%, 69% and 25% of brain metastases. Concordances rates between 
primary tumor and brain metastases were 67% for p-AKT expression, 58% for p-S6 
expression and 83% for PTEN [30]. Given this high prevalence of pathway mutations, 
it is conceivable that SNP modulate tumor cell-intrinsic behavior. Yet, it cannot be 
excluded that the SNP also determine how the host`s microenvironment interacts 
with metastatic tumor cells. 
Limitations of this study include the lack of an appropriate validation cohort and the 
lack of systematic prospective patient assessment for CNS metastasis. A separate 
analysis for patients with brain as opposed to leptomeningeal metastases would have 
been interesting, but was not feasible for lack of statistical power. Still, our results 
support the notion that the identification of risk factors for CNS metastasis may 
enable screening and earlier detection when numerous therapeutic options are still 
available, with the consequences of limiting neurological impairment and preserving 
quality of life longer. Such risk profiles may also facilitate the development of new 
strategies of prevention in populations at risk. 
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Table 1: Patient characteristics 
Table 2: Association between SNP and CNS metastases in univariate analysis, after 
Bonferroni correction, and in multivariate analysis 
Table 3: Combination of SNP and score 
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Figure legends 
Figure 1. CONSORT diagram. Patients with CNS metastases include patients with 
brain or leptomeningeal metastasis, patients without CNS metastases are defined as 
patients with extra-cerebral metastases without any neurological symptoms or signs, 
with normal brain MRI before death or during 5-years follow-up after diagnosis of first 
metastasis. 
Figure 2. Clinical correlates of CNS metastasis and outcome. A,B,C. OS from 
breast cancer diagnosis (A), first diagnosis of metastasis (B) and CNS metastasis 
diagnosis (C). D.E. Cumulative incidence of CNS metastasis after the diagnosis of 
first metastasis by hormonal and HER2 status (D) or absence or presence of tumoral 
vascular emboli (E). 
Figure 3. SNP linked to CNS metastasis. Cumulative incidence of CNS metastases 
after diagnosis of first metastasis for SNP significantly associated with CNS 
metastases on multivariate analysis. A: AKT1-RS3803304, B: PDK1-RS11686903, 
C: AKT2-RS370050, D: PI3KR1-RS706716, E: score 
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Abstract  
Introduction: The PI3K-AKT-mTOR pathway may be involved in the development of 
CNS metastasis from breast cancer. Accordingly, here we explored whether single 
nucleotide polymorphisms (SNP) of this pathway are associated with altered risk of 
CNS metastasis formation in metastatic breast cancer patients.  
Methods: The GENEOM study (NCT00959556) included blood sample collection 
from breast cancer patients treated in the neoadjuvant, adjuvant or metastatic 
setting. We identified patients with CNS metastases for comparison with patients 
without CNS metastasis, defined as absence of neurological symptoms or normal 
brain MRI before death or during 5-year follow-up. Eighty-eight SNP of PI3K-AKT-
mTOR pathway genes were selected for analysis: AKT1 (17 SNP), AKT2 (4), FGFR1 
(2), mTOR (7), PDK1 (4), PI3KR1 (11), PI3KCA (20), PTEN (17), RPS6KB1 (6). 
Results: Of 342 patients with metastases, 207 fulfilled the inclusion criteria: 107 
patients remained free of CNS metastases at last follow-up or date of death whereas 
100 patients developed CNS metastases. Among clinical parameters, hormonal and 
HER2 status as well as tumor vascular emboli were associated with risk of CNS 
metastasis. Only PI3KR1-rs706716 was associated with CNS metastasis in 
univariate analysis after Bonferroni correction (p<0.00085). Multivariate analysis 
showed associations between AKT1-rs3803304, AKT2-rs3730050, PDK1-
rs11686903 and PI3KR1-rs706716 and CNS metastasis.  
Conclusion: PI3KR1-rs706716 may be associated with CNS metastasis in metastatic 
breast cancer patients and could be included in a predictive composite score to 
detect early CNS metastasis irrespective of breast cancer subtype. 
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Text  
INTRODUCTION 
Breast cancer represents the most common cancer in women. Central nervous 
system (CNS) metastases occur in up to 10% of patients [1] and herald poor 
outcome: survival varies from 2.7 to 26.8 months with solid brain metastases, by 
breast cancer subtype [2] and is 4 months with leptomeningeal metastases [3-6]. 
Treatment of CNS metastasis aims not only for prolonging survival, but also at 
prevention or delay of neurological deterioration [7].  
The identification of patients at risk could help to increase the efficacy of treatment of 
CNS metastasis. While cerebrospinal imaging is not part of standard follow-up in 
patients without neurological signs, the identification of subgroups of patients at risk 
could allow the implementation of more intensive follow-up and early intervention 
strategies. 
Brain metastases risk is increased in triple-negative and human epidermal growth 
factor receptor (HER) 2-positive tumors [1, 8-14]. Risk factors for leptomeningeal 
metastases include opening of the ventricular system during surgery for solid brain 
metastases and resection of cerebellar metastases [15,16] and breast cancer 
patients specifically lobular subtype and triple-negative tumors [4,5,6,17]. 
Genetic variations could also help to define populations at risk. Single nucleotide 
polymorphisms (SNP) represent the most frequent type of variations of the human 
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genome [18]: they represent a single nucleotide variation at a specific position in the 
genome present at a frequency of 1%-50% in the general population that is 
maintained through heredity. While not causing disease, SNP can modify protein 
structure and function and thereby influence susceptibility to disease, including 
cancer [18]. 
The PI3K-AKT-mTOR pathway controls cell cycle, survival, differentiation, 
proliferation, motility, metabolism, and genomic stability and may be the most 
frequently activated pathway in human cancer [19,20,21]. Moreover, it also regulates 
the behavior of normal cells and contributes to host cell tumor cell interactions, e.g., 
during angiogenesis and inflammation [21-27]. PI3K-AKT-mTOR pathway genetic 
lesions are frequent in breast cancer and may mediate resistance to HER2-targeted 
agents and hormonal agents [28]. Activation of the PI3K pathway has specifically 
been observed in brain metastases from breast cancer, regardless of subtype as 
defined by hormone receptor or HER2 status [29,30], potentially mediated by the loss 
of PTEN expression as demonstrated in paired primary tumor and brain metastasis 
samples [31]. In fact, the loss of PTEN may directly promote brain invasiveness of 
metastatic breast cancer cells [27]. Here we sought to identify SNP of the PI3K-AKT-
mTOR pathway associated with increased risk of CNS metastasis formation in 
patients with metastatic breast cancer. 
 
 
MATERIALS AND METHODS 
Patients 
We conducted a secondary analysis in a subpopulation of patients from the 
GENEOM study (NCT00959556) that aimed at identifying constitutional genetic 
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variants predictive of response to chemotherapy and hormone therapy in adult 
patients with histologically confirmed breast cancer and included 914 women 
between November 2007 and January 2012. Our aim was to identify biomarkers of 
CNS metastasis risk among patients who developed metastases, at diagnosis of 
breast cancer or during follow-up (n=342) (Supplementary Note 1). Among patients 
fulfilling the inclusion criteria (n=207), CNS metastases were diagnosed at initial 
diagnosis of breast cancer or during follow-up, on brain MRI (n=87, 87%) or cranial 
CT (n=13, 13%). Histological confirmation was obtained in 10 brain metastasis 
patients. Leptomeningeal metastasis was defined by the presence of tumor cells in 
the cerebrospinal fluid (CSF) (n=25) or by characteristic MRI findings in a patient 
presenting with clinical signs suggestive of leptomeningeal metastases in the 
absence of positive CSF cytology (n=15). In 9 patients, the diagnosis was based on 
clinical evaluation and brain imaging only. Patients with extra-CNS metastasis only 
were defined by the absence of neurological symptoms or signs or normal brain MRI 
before death or during at least 5 years of follow-up after the diagnosis of the first 
metastasis. Patients with neurological symptoms of unclear origin, unclear cause of 
death, or follow-up below 5 years after the diagnosis of the first metastasis were 
excluded. 
 
SNP selection 
SNP of the PI3K-AKT-mTOR pathway were selected based on a systematic literature 
search. Eligible SNP had to have a minor allele frequency  0.05 in a European 
population, based on a 1000 genomes database 
(https://phase3browser.1000genomes.org/index.html). Eighty-eight SNP of the PI3K-
AKT-mTOR pathway were finally considered for the genomic analysis. Two were 
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excluded (AKT1 rs3803304 and AKT1-rs2498786) due to a discordance between 
frequencies observed in our population and the database. A total of 86 SNP was 
finally analyzed (Supplementary Table 1). Details on genomic analyses and SNP 
studies are provided in Supplementary Note 2. 
 
Statistical analysis 
Overall survival (OS) was defined as time interval from diagnosis until death from any 
cause using the Kaplan-Meier method. Patients alive were censored at last follow-up. 
Cumulative incidence of CNS metastases was estimated using a competing risk 
approach considering the time interval from diagnosis of first metastasis to the date 
of diagnosis of CNS metastases, with death without CNS metastases considered as 
a competing event; patients alive without CNS metastases were censored at the date 
of last follow-up. Associations between CNS metastases and clinical parameters and 
genomic parameters were evaluated using sub-distribution hazard ratios estimated in 
Fine and Gray regression models. The first step consisted in the analysis of clinical 
factors. A multivariate competing risk regression model was performed for 
parameters significantly associated with CNS metastasis in univariate analysis 
(p<0.05). 
A similar type of modeling was used for the second step of the analysis, evaluating 
the association of genomic parameters with the risk of CNS metastases. A SNP was 
considered as evaluable after verification of comparison for genotypic frequencies 
according to the Hardy-Weinberg equilibrium. SNP were excluded if the minor allele 
frequency was below 1%, or if genotyping analyses were performed in less than 90% 
of the patients of the cohort. Patients with less than 90% of SNP analyzed were 
excluded. For each SNP, the analysis was performed considering a dominant model 
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(dominant genotype versus others), recessive model (recessive genotype versus 
others) or log-additive model (3 ordered genotypic classes). The significance level 
was set to p<0.05, and a Bonferroni correction for multiple testing was also 
determined according to the number of independent SNP evaluated 
(threshold=0.05/number of independent SNP with r2<0.8). SNP significantly 
associated with CNS metastasis in univariate analysis (using level p<0.05) were 
included in a multivariate competitive risks regression model including a step by step 
selection procedure of variables. Akaike information criterion (AIC) was applied for 
the selection of the appropriate SNP coding when several modellings were 
associated with CNS metastasis. A composite score was also computed from the 
estimated regression coefficients of the multivariate model including all SNP 
significant at a 5%-significant level. Lastly, the association of this genomic score with 
the risk of CNS metastases was evaluated in multivariate analysis adjusted for 
clinical parameters significantly linked to CNS metastasis. Confidence intervals were 
re-estimated using a boostrap approach with 1000 samplings. Harrell C 
discrimination index was computed. Statistical analyses were performed using Stata 
software (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, 
TX: StataCorp LP) and SNPassoc package of R software v3.3.1. 
 
RESULTS 
Clinical patient characteristics 
Among the 914 patients enrolled in GENEOM, 342 patients had metastatic disease, 
119 at diagnosis of breast cancer and 223 during follow-up. Among these 342 
patients, 135 patients were excluded, leading to a study population of 207 patients 
(Figure 1). The median follow-up of this cohort is 9.1 years (range 4.8-10.5) after the 
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diagnosis of first metastasis. Overall, 107 patients remained free of CNS metastases 
at last follow-up or date of death whereas 100 patients developed CNS metastases. 
Median time interval between first diagnosis of metastasis and first diagnosis of brain 
metastasis was 1.4 years (0-8.4); it was 2.1 years between first diagnosis of 
metastasis and first diagnosis of leptomeningeal metastasis. CNS metastasis was 
the first metastatic site in 8 patients (8%). Treatment of brain metastases included 
surgery in 10, stereotactic radiotherapy in 14, whole brain radiotherapy in 51, and 
pharmacotherapy in 53 patients. Treatment of leptomeningeal disease included intra-
cerebrospinal fluid pharmacotherapy in 28, focal radiotherapy in 5 and whole brain 
radiotherapy in 1, and systemic pharmacotherapy in 29 patients. At last follow-up, 
189 patients had died. Median overall survival was 5.3 years (95% CI 4.5-6.1) since 
breast cancer diagnosis and 2.8 years (95% CI 2.3-3.3) since first diagnosis of 
metastasis. Median overall survival after diagnosis of CNS metastasis was 4.7 
months (95% CI: 3.6-6.4) for brain metastases patients and 4 months (95% CI: 2.3-
4.9) for leptomeningeal metastases patients (Figure 2A,B,C).  
Patient characteristics and association of clinical characteristics with risk of CNS 
metastases are summarized in Table 1. Median age at breast cancer diagnosis was 
50 years (range, 22 to 79); age was not associated with occurrence of CNS 
metastasis. A lower time interval between breast cancer diagnosis and diagnosis of 
first metastasis was associated with an increased risk of CNS metastases whereas 
histology and Scarff Bloom Richardson scores were not. Cumulative incidence of 
CNS metastases was higher in patients with hormone receptor-positive and HER2-
positive or triple-negative tumors, as well as in patients with peritumoral emboli on 
univariate and multivariate analysis (Figure 2D,E). Initial treatment was not 
associated to the occurrence of CNS metastases (Supplementary Table 2).  
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SNP analyses 
Of 86 SNP, 3 were excluded from analysis: RPS56KB1-rs1292033 for not respecting 
the Hardy Weinberg equilibrium, and PI3KCA-rs17849071 and PI3KCA-rs7641889 
because 10.1% of patients could not be genotyped for these 2 SNP. No SNP had a 
minority allele frequency below 1%. The genotype of all patients was analyzed for 
more than 90% of SNP, and thus all patients were included in this analysis. Thus 83 
SNP were finally evaluated (Supplementary Table 1). Univariate analysis showed a 
significant association at a 5%-alpha level between the 7 of 83 SNP and the 
occurrence of CNS metastasis: AKT1-rs3803304, AKT2-rs3730050, AKT2-
rs8100018, PDK1-rs11686903, PDK1-rs11904366, PI3KR1-rs251408 and PI3KR1-
rs706716 (Table 2). After Bonferroni correction (p-value<0.00085), only PI3KR1-
rs706716 remained significantly associated with CNS metastasis. For the multivariate 
analysis including SNP associated with occurrence of CNS metastasis in univariate 
analysis at the 5%-alpha level, we excluded AKT2-rs8100018 since it had an 
identical distribution as AKT2-rs370050 in our population. Multivariate analysis 
confirmed an association between AKT1-rs3803304 CC, AKT2-rs3730050 AA, 
PDK1-rs11686903 TT and PI3KR1-rs706716 TT and the occurrence of CNS 
metastases (Table 2, Figure 3) with similar strength of association. When these 4 
SNP were combined into a score, three prognostic groups could be identified: five-
year cumulative incidence of CNS metastasis rate were 34.8%, 68.9% and 85.7% for 
patients with a score of 0 (no risk genotype), 1 (1 risk genotype) and 2 (2 risk 
genotypes). The score was significantly associated with the occurrence of CNS 
metastasis, with and without adjustment for the significant clinical parameters, 
hormone receptor status and HER2 status and peritumoral emboli (Table 3). 
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Confidence intervals of sub-distribution hazard ratios were re-estimated using a 
bootstrap approach and were close to the results previously obtained. The C index of 
Harrell, evaluating the discriminant capacity of the score was 0.607 (95%CI: 0.557-
0.657). The interaction test between the score and clinical parameters was not 
significant for both hormone receptors status and HER2 status, and peritumoral 
emboli (Supplementary Table 3). 
 
 
DISCUSSION 
CNS metastases are a frequent and life-threatening complication of metastatic breast 
cancer that not only limits survival, but induces morbidity and greatly impairs quality 
of life. The established risk factors of CNS metastasis such as HER2-positive and 
triple-negative tumor status [1, 9-14, 32] were confirmed in the present cohort. 
Interestingly, we observed that peritumoral emboli were also associated with 
increased risk of CNS metastasis (Table 1, Figure 2E). We sought to explore 
variations of PI3K-AKT-mTOR pathway genes for association with increased risk of 
CNS metastasis in metastatic breast cancer. AKT1-rs3803304, AKT2-rs3730050, 
AKT2-rs8100018, PDK1-rs11686903, PDK1-rs11904366, PI3KR1-rs251408 and 
PI3KR1-rs706716 were associated with risk of CNS metastasis in univariate analysis 
at a 5% alpha level, however, after Bonferroni correction, only PI3KR1-rs706716 
remained significantly associated (Table 2). Multivariate analysis confirmed 
associations between AKT1-rs3803304, AKT2-rs3730050, PDK1-rs11686903 and 
PI3KR1-rs706716, and the risk of CNS metastasis. The risk was at least double for 
patients with AKT1-rs3803304 (CC), AKT2-rs3730050 (AA), PDK1-rs11686903 (TT) 
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and PI3KR1-rs706716 (TT). The combination of SNP into a score enhanced the 
predictive power (Table 3). 
None of these SNP has previously been reported in studies on CNS metastases or 
breast cancer. PI3KR1-rs706716 and PDK1-rs11686903 have not been associated 
with other diseases. AKT1-rs3803304 was associated with a lower risk of death in 45 
patients with recurrent or initially metastatic head and neck squamous cell carcinoma 
[33] and a better response to treatment was associated with this SNP in 45 
esophageal cancer patients with adenocarcinoma or squamous cell carcinoma who 
had undergone chemoradiotherapy and surgery [34]. AKT2-rs3730050 was 
associated with shorter survival in 319 patients with muscle-invasive and metastatic 
bladder cancer [35].  
An analysis of 16 SNP of 5 genes of the PI3K-AKT-mTOR pathway (PIK3CA, PTEN, 
AKT1, AKT2, FRAP1) and occurrence of brain metastases in 317 non-small cell lung 
cancer patients showed that AKT1-rs2498804, AKT1-rs2494732 and PIK3CA-
rs2699887 increased the risk of brain metastases at 24-months follow-up [36]. None 
of these SNP were identified as at risk of CNS metastases here. 
How precisely SNP in a given pathway modulate course of disease in cancer patients 
remains to be elucidated. PI3KCA mutations are the most common mutations of the 
PI3K pathway in breast cancer, depending on the subtype of cancer, with the lowest 
rate in triple negative cancer. The prognostic role of PI3KCA mutations remains 
controversial, but they tend to be associated with more favorable outcomes [28]. 
Other alterations of the PI3K-AKT-mTOR pathway in breast cancer include PI3KR1 
mutations (3%), decreased PI3KR1 expression (62%), AKT1 mutations (3%) and 
overexpression (25.3%), PTEN mutations (2-12.5%), and PTEN loss (28%) [20, 28, 
37]. An alteration of at least one parameter of PI3K pathway has been reported in 
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72% of tumors [37]. Among 52 breast cancer brain metastases and 12 matched 
primary breast cancers, expression of p-AKT and p-S6, and lack of PTEN expression 
were found in 75%, 69% and 25% of brain metastases. Concordances rates between 
primary tumor and brain metastases were 67% for p-AKT expression, 58% for p-S6 
expression and 83% for PTEN [30]. Given this high prevalence of pathway mutations, 
it is conceivable that SNP modulate tumor cell-intrinsic behavior. Yet, it cannot be 
excluded that the SNP also determine how the host`s microenvironment interacts 
with metastatic tumor cells. 
Limitations of this study include the lack of an appropriate validation cohort and the 
lack of systematic prospective patient assessment for CNS metastasis. A separate 
analysis for patients with brain as opposed to leptomeningeal metastases would have 
been interesting, but was not feasible for lack of statistical power. Still, our results 
support the notion that the identification of risk factors for CNS metastasis may 
enable screening and earlier detection when numerous therapeutic options are still 
available, with the consequences of limiting neurological impairment and preserving 
quality of life longer. Such risk profiles may also facilitate the development of new 
strategies of prevention in populations at risk. 
 
 
TABLES TITLES AND FIGURES LEGENDS 
Tables  
Table 1: Patient characteristics 
Table 2: Association between SNP and CNS metastases in univariate analysis, after 
Bonferroni correction, and in multivariate analysis 
Table 3: Combination of SNP and score 
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Figure legends 
Figure 1. CONSORT diagram. Patients with CNS metastases include patients with 
brain or leptomeningeal metastasis, patients without CNS metastases are defined as 
patients with extra-cerebral metastases without any neurological symptoms or signs, 
with normal brain MRI before death or during 5-years follow-up after diagnosis of first 
metastasis. 
Figure 2. Clinical correlates of CNS metastasis and outcome. A,B,C. OS from 
breast cancer diagnosis (A), first diagnosis of metastasis (B) and CNS metastasis 
diagnosis (C). D.E. Cumulative incidence of CNS metastasis after the diagnosis of 
first metastasis by hormonal and HER2 status (D) or absence or presence of tumoral 
vascular emboli (E). 
Figure 3. SNP linked to CNS metastasis. Cumulative incidence of CNS metastases 
after diagnosis of first metastasis for SNP significantly associated with CNS 
metastases on multivariate analysis. A: AKT1-RS3803304, B: PDK1-RS11686903, 
C: AKT2-RS370050, D: PI3KR1-RS706716, E: score 
 
Supplementary material 
Supplementary Note 1: Demographic and clinical data collected for the analysis 
Supplementary Note 2: Details on genomic analyses and SNP studies 
Supplementary Table 1: Genes and Single Nucleotide Polymorphism selected for this 
study 
Supplementary Table 2: No association between initial treatment of breast cancer 
and risk of CNS metastases 
Supplementary Table 3: Interaction test between the score and clinical parameters  
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TABLES  
 
Table 1: Patient characteristics and association with risk of CNS metastases 
 
   Univariate analysis (clinical factors) Multivariate analysis (clinical factors) 
 N (%) 5-year cumulative incidence  
of CNS metastases (95% CI) 
 
SHR (95% CI) p-value SHR (95% CI) p-value 
Age at breast cancer diagnosis (/year)  - 0.992 (0.976-1.010) 0.39 n.a.  n.a. 
Time between breast cancer diagnosis  
and first diagnosis of metastasis (/month) 
  
- 
 
0.994 (0.991-0.998) 
 
0.007 
 
0.995 (0.989-1.000) 
 
0.051 
Histology 
 Infiltrative ductal carcinoma 
 Infiltrative lobular carcinoma 
 Other 
 
155 (75.2%) 
19 (9.2%) 
32 (15.5%) 
 
45.1% (37.2-52.8) 
21.1% (6.6-41.0) 
53.1% (34.7-68.5) 
 
1 
0.36 (0.13-1.001) 
1.44 (0.95-2.20) 
 
 
0.06 
0.09 
 
 
n.a. 
n.a. 
 
 
 n.a. 
 n.a. 
SBR grade 
 I 
 II 
 III 
 Other (non gradable/ not avalaible) 
 
14 (6.8%) 
109 (52.7%) 
49 (23.7%) 
35 (16.9%) 
 
28.6% (8.8-52.4) 
43.1% (33.7-52.2) 
59.2% (44.2-71.4) 
30.4% (13.5-49.3) 
 
1 
1.93 (0.70-5.37) 
2.70 (0.95-7.68) 
1.43 (0.44-4.62) 
 
 
0.21 
0.06 
0.55 
 
 
n.a. 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
HR and HER2 status 
 Hormone receptor-positive, HER2-negative 
 Hormone receptor-positive, HER2-positive 
 Hormonel receptor-negative, HER2-positive 
 Triple-negative 
 
108 (56.5%) 
33 (17.3%) 
24 (12.6%) 
26 (13.6%) 
 
35.2% (26.3-44.2) 
51.5% (33.5-66.9) 
58.3% (36.5-75.0) 
69.2% (47.8-83.3) 
 
1 
1.77 (1.06-2.96) 
1.81 (0.98-3.33) 
2.54 (1.43-4.51) 
 
 
0.028 
0.057 
0.001 
 
1 
1.70 (1.03-2.79) 
1.32 (0.63-2.75) 
2.10 (1.16-3.79) 
 
 
0.037 
0.45 
0.014 
Peritumoral vascular emboli 
 No 
 Yes  
 
127 (69.8%) 
55 (30.2%) 
 
40.9% (32.4-49.3) 
58.2% (44.1-69.9) 
 
1 
1.78 (1.18-2.68) 
 
 
0.006 
 
1 
1.83 (1.20-2.77) 
 
 
0.005 
Presence of metastatic sites:  
 at diagnosis or whithin 3 months  
after breast cancer diagnosis 
 > 3 months after breast cancer diagnosis 
 
71 (34.3%) 
 
136 (65.7%) 
 
40.9% (29.4-51.9) 
45.6% (37.1-53.7) 
 
1 
1.28 (0.83-1.96) 
 
 
0.26 
 
 
n.a. 
 
 
n.a. 
Metastastic sites at first diagnosis of metastases: 
Bone metastasis 
 No 
 Yes 
 
 
91 (44.0%) 
116 (56.0%) 
 
 
48.5% (37.8-58.1) 
40.5% (31.6-49.3) 
 
 
1 
0.75 (0.51-1.11) 
 
 
 
0.15 
 
 
 
n.a. 
 
 
 
n.a. 
Lung metastasis  
 No 
 
141 (68.1%) 
 
41.1% (33.0-49.1) 
 
1 
 
 
 
 
 
 
Table
 Yes 66 (31.9%) 50.0% (37.5-61.3) 1.30 (0.87-1.95) 0.20 n.a. n.a. 
Pleura metastasis  
 No 
 Yes 
 
190 (91.8%) 
17 (8.2%) 
 
43.7% (36.6-50.6) 
47.1% (23.0-68.0) 
 
1 
1.08 (0.49-2.39) 
 
 
0.85 
 
 
n.a. 
 
 
n.a. 
Mediastinum metastasis  
 No 
 Yes 
 
156 (75.4%) 
51 (24.6%) 
 
43.0% (35.1-50.5) 
47.1% (33.0-59.9) 
 
1 
1.13 (0.72-1.78) 
 
 
0.58 
 
 
n.a. 
 
 
n.a. 
Liver metastasis  
 No 
 Yes 
 
121 (58.5%) 
86 (41.5%) 
 
41.3% (32.5-49.9) 
47.7% (36.8-57.7) 
 
1 
1.14 (0.77-1.70) 
 
 
0.51 
 
 
n.a. 
 
 
n.a. 
Peritoneum metastasis  
 No 
 Yes 
 
199 (96.1%) 
8 (3.9%) 
 
44.7% (37.7-51.5) 
25.0% (3.7-55.8) 
 
1 
0.50 (0.10-2.18) 
 
 
0.33 
 
 
n.a. 
 
 
n.a. 
Cutaneous metastasis  
 No 
 Yes 
 
178 (86.0%) 
29 (14.0%) 
 
42.7% (35.4-49.8) 
51.7% (32.5-67.9) 
 
1 
1.27 (0.74-2.18) 
 
 
0.38 
 
 
n.a. 
 
 
n.a. 
Loco-regional metastasis  
 No 
 Yes 
 
117 (56.5%) 
90 (43.5%) 
 
38.5% (29.7-47.2) 
51.1% (40.4-60.9) 
 
1 
1.35 (0.92-2.00) 
 
 
0.13 
 
 
n.a. 
 
 
n.a. 
Other metastasis  
 No 
 Yes 
 
185 (89.4%) 
22 (10.6%) 
 
42.2% (35.0-49.2) 
59.1% (36.1-76.2) 
 
1 
1.72 (0.88-3.33) 
 
 
0.11 
 
 
n.a. 
 
 
n.a. 
 
CNS : central nervous system; SBR: Scarff Bloom Richardson 
SHR: Sub-distribution hazard ratio estimated in Fine and Gray model 
Multivariate analysis included: HR and HER2 status, peritumoral vascular emboli, time between breast cancer diagnosis and first diagnosis of metastasis. 
n.a.: not applicable because not included in multivariate regression model (p>0.05 in univariate analysis) 
 
  
Table 2: Association between SNP and CNS metastases in univariate analysis, after Bonferroni correction, and in multivariate 
analysis, for the 7 SNP with p-values <0.05 on univariate analysis 
 
   Univariate analysis (SNP) Multivariate analysis (SNP) 
SNP N 5-year cumulative incidence  
of CNS metastases (95% CI) 
 
SHR (95% CI) p-value AIC Significance  
After Bonferroni 
 correction 
 (0.00085) 
Regression  
coefficient 
SHR (95% CI) p-value 
AKT1-RS3803304  
CG-GG 
CC (recessive)  
 
198  
9  
 
42.9% (36.0-49.7) 
66.7% (28.2-87.8) 
 
1 
2.17 (1.06-4.42)  
 
 
0.033  
 
 
1003.0  
 
 
NS 
 
 
1.00  
 
1 
2.72 (1.30-5.68) 
 
 
0.008 
AKT2 - RS3730050  
AG-GG 
AA (recessive)  
 
189  
18  
 
41.8% (34.7-48.7) 
66.7% (40.4-83.4) 
 
1 
2.07 (1.06-4.02)  
 
 
0.033  
 
 
1001.5  
 
 
NS 
 
 
0.73 
 
1 
2.06 (1.03-4.14) 
 
 
0.041 
AKT2 - RS8100018  
CG-GG 
CC (recessive)  
 
189  
18  
 
41.8% (34.7-48.7) 
66.7% (40.4-83.4) 
 
1 
2.07 (1.06-4.02)  
 
 
0.033  
 
 
1001.5  
 
 
NS 
 
 
ND 
  
PDK1-RS11686903  
CC-CT 
TT (recessive)   
 
Log-additive :  
CC 
CT 
TT  
 
184  
23  
 
 
75  
109  
23  
 
40.2% (33.1-47.2) 
73.9% (50.9-87.3) 
 
 
36.0% (25.3-46.8) 
43.1% (33.7-52.2) 
73.9% (50.9-87.3) 
 
1 
2.35 (1.37-4.02) 
  
1.57 (1.13-2.18)  
 
 
0.002  
 
0.007  
 
 
997.7  
 
998.3  
 
 
NS 
 
NS 
 
 
0.87 
 
1 
2.38 (1.40-4.05) 
 
 
0.001 
PDK1-RS11904366  
GT-TT 
GG (dominant)  
 
Log-additive :  
GG 
GT 
TT  
 
68  
139  
 
 
139  
62  
6  
 
32.4% (21.7-43.5) 
49.6% (41.1-57.6) 
 
 
49.6% (41.1-57.6) 
33.9% (22.5-45.6) 
16.7% (0.8-51.7) 
 
1 
1.67 (1.06-2.63)  
 
1.57 (1.04-2.39)  
 
 
0.028  
 
0.033  
 
 
1000.8  
 
1000.9  
 
 
NS 
 
NS 
 
 
NS* 
  
PI3KR1-RS251408  
AA-AG 
GG (recessive)  
 
173  
34  
 
40.5% (33.1-47.7) 
61.8% (43.4-75.7) 
 
1 
1.62 (1.03-2.54)  
 
 
0.035  
 
 
1002.5  
 
 
NS 
 
 
NS* 
  
PI3KR1-RS706716  
CC-CT 
TT (recessive)  
 
198  
9  
 
41.9% (35.0-48.7) 
88.9% (43.3-98.4) 
 
1 
3.16 (1.71-5.87)  
 
 
0.0003  
 
 
999.0  
 
 
S 
 
 
0.88 
 
1 
2.42 (1.12-3.25) 
 
 
0.025 
 
SHR: Sub-distribution hazard ratio estimated in Fine and Gray model 
Univariate analysis : NS : non significant, S : significant after Bonferroni correction for multiple testing 
The backward stepwise multivariate regression model included : AKT1-RS3803304, AKT2 - RS3730050, PDK1-RS11686903 (as recessive), PDK1-RS11904366 (as 
dominant), PI3KR1-RS251408, and PI3KR1-RS706716. PDK1-RS11686903 and PDK1-RS11904366 were included as recessive and dominant because of a lower AIC 
obtained in univariate analysis than with log-additive model.  
ND : not done : AKT2 - RS8100018 was not included in multivariate analysis because of its identical distribution with AKT2 - RS3730050 in our population 
NS*: SNPs that were not significant and removed from backward stepwise multivariate regression model (p-value=0.15 for PDK1 - RS11904366 and p-value=0.38 for PI3KR1 - 
RS251408). 
 
 
 
 
 
 
 
  
Table 3 : Combination of SNP and score 
 
 
 
   Original hazard ratio Boostrap analysis 
 Number of 
patients 
5-year 
cumulative 
incidence  
of CNS 
metastases 
(95% CI) 
 
SHR (95% 
CI) 
p-value SHR (95% CI) 
adjusted for 
clinical 
parameters* 
p-value SHR (95% CI) p-value SHR (95% CI) 
adjusted for 
clinical 
parameters* 
p-value 
SCORE 0 155 34.8% 
(27.4-42.3) 
1  1  1  1  
SCORE 1 45 68.9% 
(53.2-80.3) 
2.55 (1.65-
3.94) 
<0.001 2.07 (1.30-3.30) 0.002 2.55 (1.60-4.07) <0.001 2.07 (1.26-3.42) 0.004 
SCORE 2 7 85.7% 
(33.4-97.9) 
4.62 (1.82-
11.7) 
0.001 3.82 (1.39-10.5) 0.009 4.62 (1.53-13.9) 0.007 3.82 (0.40-36.9) 0.25 
           
SCORE 
(continuous 
value) 
  2.32 (1.64-
3.30) 
<0.001 2.01 (1.37-2.95) <0.001 2.32 (1.61-3.36) <0.001 2.01 (1.34-3.03) 0.001 
SHR: Sub-distribution hazard ratio estimated in Fine and Gray model 
* Adjustment for estrogen and progesterone receptors, HER2 status, peritumoral emboli 
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